As the world navigates the greatest public health crisis in recent memory, the biopharma industry has taken a leading role in fighting COVID-19. How can we measure our ability to deliver on not only this challenge, but others that are to come?

Research to foster industry learning and growth

In collaboration with Longitude, a Financial Times company, Cytiva has developed the Global Biopharma Resilience Index. This index uses survey response data to rank biopharma capabilities and resilience in 20 countries, scoring each on five factors critical to meeting global demand during a public health crisis:

  • Supply chain resilience
  • Access to talent
  • Strength of the R&D ecosystem
  • Quality and agility of manufacturing processes
  • Effectiveness of government policy in supporting the industry

What key insights have the Global Biopharma Resilience Index revealed so far?

In summary, recent data shows there is work to be done to secure supply chains of the future — the biopharma industry is currently underperforming across all five of the critical areas measured in the index. To touch on some specifics, this study suggests we must bridge the gap between high and low income countries to avert shortages of critical drug supplies. Disruptions to global supply chains have also exposed domestic markets that are lacking support for talent and manufacturing.

How can industry players use this information to improve?

The Global Biopharma Resilience Index provides a measure of the biopharma industry’s strength and allows countries to learn from each other in tackling challenges, now and beyond the pandemic. Through the application of these results and insights from leading experts, our industry has the opportunity to learn from current limitations, adapt, and blaze a trail forward to a more resilient future.

For more study highlights, key findings, and the state of biopharma amidst its biggest challenge yet, read the articles below.

Global Biopharma Resilience Index five areas